Eli Lilly and

Company snapshot

Eli Lilly and maintains 107 tracked programs across Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer, Overweight, Obesity, Diabetes Mellitus, Type 1, Migraine, Alzheimer Disease, Obesity, Peripheral Arterial Disease, Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes. Momentum score: n/a/100 (30-day delta: n/a). Public

• 107 active pipeline program(s) linked via ClinicalTrials.gov.
• 107 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Eli Lilly and. Not investment advice.

• Peer + 0 momentum

  Takeda

  TA overlap score 50

• Peer + 0 momentum

  vTv Therapeutics

  TA overlap score 42.8

• Peer + 0 momentum

  Eli Lilly and

  TA overlap score 42.4

• Peer + 0 momentum

  AstraZeneca

  TA overlap score 40

• Peer + 0 momentum

  AbbVie Deutschland GmbH

  TA overlap score 40

• Peer + 0 momentum

  Hospital Authority

  TA overlap score 40

• Peer + 0 momentum

  IONIS PHARMACEUTICALS

  TA overlap score 40

• Peer + 0 momentum

  Novartis India

  TA overlap score 40

• Peer + 0 momentum

  NovoThirteen

  TA overlap score 38.8

• Peer + 0 momentum

  LIGAND PHARMACEUTICALS

  TA overlap score 26.8

Recent activity

Latest pipeline, patent, and corporate events for Eli Lilly and.

1. Jun 8, 2026 Clinical update

   I3Y-MC-JPEI — Phase 1

2. Jun 8, 2026 Clinical update

   I3Y-MC-JPCE — Phase 1

3. Jun 8, 2026 Clinical update

   LOXO-PIK-21001 — Phase 1

4. Jun 8, 2026 Clinical update

   LOXO-LNC-24001 — Phase 1

5. Jun 8, 2026 Clinical update

   LOXO-IDH-20001 — Phase 1

View all clinical trial activity →

• What is Eli Lilly and?

  Eli Lilly Co is a pharma organization headquartered in EU. Primary therapeutic focus areas include Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis, Type 2 Diabetes Mellitus, Breast Cancer. NovaPharmaNews links 107 clinical program(s), 0 drug profile(s), and 0 patent reco

• Is Eli Lilly and publicly traded?

  Eli Lilly and appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Eli Lilly and develop or market?

  We link 99 drug profile(s) where Eli Lilly and is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/eli-lilly-co#company-drugs.

• What are the latest developments for Eli Lilly and?

  In the last 12 months our linked public records show 107 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Eli Lilly and focus on?

  Eli Lilly and focuses on Obesity, Overweight, Type 2 Diabetes, Ulcerative Colitis based on our analysis of their pipeline programs and drug development activities.